Innovation And ExpertiseThe involvement of top scientists and physicians in Biohaven's R&D review day highlights the credibility and expertise backing its research programs.
Pipeline DevelopmentBHV-1300 demonstrated significant reductions in IgG, suggesting potential benefits for conditions like Graves' Disease and Myasthenia Gravis.
Regulatory ProcessManagement sounded very confident in the SCA regulatory process, indicating its responses to the FDA’s questions were fairly easy and quick.